Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2015

01-09-2015 | Original Article

Rapid Growth Rates of Suspected Pancreatic Cyst Branch Duct Intraductal Papillary Mucinous Neoplasms Predict Malignancy

Authors: Wilson T. Kwong, Robert D. Lawson, Gordon Hunt, Syed M. Fehmi, James A. Proudfoot, Ronghui Xu, Andrew Giap, Raymond S. Tang, Ingrid Gonzalez, Mary L. Krinsky, Thomas J. Savides

Published in: Digestive Diseases and Sciences | Issue 9/2015

Login to get access

Abstract

Background

The majority of branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) are recommended for surveillance imaging based on consensus guidelines. However, growth rates that should prompt concern for malignant transformation of BD-IPMN are unknown.

Aims

To determine whether BD-IPMN growth can predict an increased risk of malignancy and define growth rates concerning for malignant BD-IPMN.

Methods

The study is a retrospective, multicenter study of suspected BD-IPMN patients undergoing imaging surveillance. All patients underwent EUS evaluation followed by surveillance imaging.

Results

Two hundred and eighty-four patients with suspected BD-IPMN without worrisome features or high-risk stigmata were followed for a median 56 months and underwent a median of four imaging studies. Nine patients (3.2 %) developed malignant BD-IPMN. Malignant BD-IPMN grew at a faster rate (18.6 vs. 0.8 mm/year; P = 0.05) compared to benign BD-IPMN. BD-IPMN growth rate between 2 and 5 mm/year was associated with an increased risk of malignancy with hazard ratio (HR) of 11.4 (95 % CI 2.2–58.6) when compared to subjects with BD-IPMN growth rate <2 mm/year (P = 0.004). BD-IPMN growth rate ≥5 mm/year had a hazard ratio of 19.5 (95 % CI 2.4–157.8) (P = 0.005). BD-IPMN growth rate of 2 mm/year had a sensitivity of 78 %, specificity of 90 %, and accuracy of 88 % to identify malignancy. Total BD-IPMN growth was also associated with increased risk of malignancy (P = 0.003) with all malignant IPMNs growing at least 10 mm prior to cancer diagnosis.

Conclusions

BD-IPMN growth rates ≥2 mm/year and total growth of ≥10 mm should be considered worrisome features for BD-IPMN at increased risk of malignancy.
Literature
1.
go back to reference Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197.CrossRefPubMed Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197.CrossRefPubMed
2.
go back to reference Vege S, Ziring B, Jain R, et al. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–822.CrossRefPubMed Vege S, Ziring B, Jain R, et al. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–822.CrossRefPubMed
3.
go back to reference Jang JY, Park T, Lee S. Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. Br J Surg. 2014;101:686–692.CrossRefPubMed Jang JY, Park T, Lee S. Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. Br J Surg. 2014;101:686–692.CrossRefPubMed
4.
go back to reference Kim KW, Park SH, Pyo J, et al. Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas; a meta-analysis. Ann Surg. 2014;259:72–81.CrossRefPubMed Kim KW, Park SH, Pyo J, et al. Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas; a meta-analysis. Ann Surg. 2014;259:72–81.CrossRefPubMed
5.
go back to reference Shimizu Y, Yamaue H, Maguchi H, et al. Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers. Pancreas. 2013;42:883–888.CrossRefPubMed Shimizu Y, Yamaue H, Maguchi H, et al. Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers. Pancreas. 2013;42:883–888.CrossRefPubMed
6.
go back to reference Kang MJ, Jang JY, Kim SJ, et al. Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol. 2011;9:87–93.CrossRefPubMed Kang MJ, Jang JY, Kim SJ, et al. Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol. 2011;9:87–93.CrossRefPubMed
7.
go back to reference Bae SY, Lee KT, Lee JH, Lee JK, Lee KH, Rhee JC. Proper management and follow-up strategy of branch duct intraductal papillary mucinous neoplasms of the pancreas. Dig Liver Dis. 2012;44:257–260.CrossRefPubMed Bae SY, Lee KT, Lee JH, Lee JK, Lee KH, Rhee JC. Proper management and follow-up strategy of branch duct intraductal papillary mucinous neoplasms of the pancreas. Dig Liver Dis. 2012;44:257–260.CrossRefPubMed
8.
go back to reference R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014.
9.
go back to reference Therneau T (2014) A package for survival analysis in S. R package version 2.37-7. Therneau T (2014) A package for survival analysis in S. R package version 2.37-7.
10.
go back to reference Yamaguchi T, Baba T, Ishihara T, et al. Long-term follow-up of intraductal papillary mucinous neoplasm of the pancreas with ultrasonography. Clin Gastroenterol Hepatol. 2005;3:1136–1143.CrossRefPubMed Yamaguchi T, Baba T, Ishihara T, et al. Long-term follow-up of intraductal papillary mucinous neoplasm of the pancreas with ultrasonography. Clin Gastroenterol Hepatol. 2005;3:1136–1143.CrossRefPubMed
11.
go back to reference Maimone S, Agrawal D, Pollack MJ, et al. Variability in measurements of pancreatic cyst size among EUS, CT, and magnetic resonance imaging modalities. Gastrointest Endosc. 2010;71:945–950.CrossRefPubMed Maimone S, Agrawal D, Pollack MJ, et al. Variability in measurements of pancreatic cyst size among EUS, CT, and magnetic resonance imaging modalities. Gastrointest Endosc. 2010;71:945–950.CrossRefPubMed
Metadata
Title
Rapid Growth Rates of Suspected Pancreatic Cyst Branch Duct Intraductal Papillary Mucinous Neoplasms Predict Malignancy
Authors
Wilson T. Kwong
Robert D. Lawson
Gordon Hunt
Syed M. Fehmi
James A. Proudfoot
Ronghui Xu
Andrew Giap
Raymond S. Tang
Ingrid Gonzalez
Mary L. Krinsky
Thomas J. Savides
Publication date
01-09-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3679-8

Other articles of this Issue 9/2015

Digestive Diseases and Sciences 9/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.